Discounted Cash Flow (DCF) Analysis Levered
Centessa Pharmaceuticals plc (CNTA)
$3.62
-0.25 (-6.46%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
Revenue | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|
Revenue (%) | |||||||
Operating Cash Flow | - | - | - | - | - | - | - |
Operating Cash Flow (%) | |||||||
Capital Expenditure | - | - | - | - | - | - | - |
Capital Expenditure (%) | |||||||
Free Cash Flow | - | - | - | - | - | - | - |
Weighted Average Cost Of Capital
Share price | $ 3.62 |
---|---|
Beta | 0.000 |
Diluted Shares Outstanding | 94.02 |
Cost of Debt | |
Tax Rate | -0.03 |
After-tax Cost of Debt | 1.55% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 3.532 |
Total Debt | 75.70 |
Total Equity | 340.35 |
Total Capital | 416.05 |
Debt Weighting | 18.19 |
Equity Weighting | 81.81 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2020 Projected | 2021 Projected | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
Revenue | - | - | - | - | - | - | - |
---|---|---|---|---|---|---|---|
Operating Cash Flow | - | - | - | - | - | - | - |
Capital Expenditure | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
WACC | |||||||
PV LFCF | - | - | - | - | - | - | - |
SUM PV LFCF | - |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 3.17 |
Free cash flow (t + 1) | - |
Terminal Value | - |
Present Value of Terminal Value | - |
Intrinsic Value
Enterprise Value | - |
---|---|
Net Debt | -519.38 |
Equity Value | - |
Shares Outstanding | 94.02 |
Equity Value Per Share | - |